We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Image: Bigstock
Why is Biogen (BIIB) Stock Plunging Today?
On Tuesday, shares of biopharmaceutical company Biogen (BIIB - Free Report) are plunging, down over 15% in afternoon trading after the company’s Phase 2 study of its treatment for relapsing multiple sclerosis failed to meet its primary and secondary endpoints.
The drug, opicinumab, did not meet the primary objective of the improvement of physical and cognitive function and disability, while the secondary objective was slowing of disability progression.
"Achieving repair of the human central nervous system through remyelination would be a substantial achievement, and while we missed the primary endpoint, the SYNERGY study results suggest evidence of a clinical effect of opicinumab," said Chief Medical Officer Alfred Sandrock. "Due to the complex nature of the data set, we continue to analyze the results to inform the design of our next study."
Biogen added that opicinumab was generally well tolerated and showed a linear, well-behaved PK profile over the studied dose range.
So far this year, BIIB has underperformed the broader markets, dropping over 5% as of Monday’s close.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>